A. Deodhar

发表

Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis

A. Deodhar, A. Blauvelt, K. Vakil-Gilani, 2015, Clinical, cosmetic and investigational dermatology.

Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience

A. Bhushan, G. Maresh, A. Deodhar, 2021, Rheumatology International.

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

M. Lebwohl, C. Griffiths, P. Primatesta, 2021, British Journal of Dermatology.

Nutritional Evaluation of Accelerated Ripened Cheddar Processed Cheese

A. Deodhar, Veena Tomar, 1985 .

EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY

P. Mease, R. Fleischmann, D. Kielar, 2012 .

POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL

D. M. van der Heijde, A. Pangan, X. Bu, 2022, Annals of the Rheumatic Diseases.

OP0016 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL

D. M. van der Heijde, F. E. Van den Bosch, D. Poddubnyy, 2022, Annals of the Rheumatic Diseases.

POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY

D. M. van der Heijde, L. Gensler, M. Magrey, 2022, Annals of the Rheumatic Diseases.

OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY

M. Dougados, D. M. van der Heijde, L. Gensler, 2022, Annals of the Rheumatic Diseases.

SAT0268 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis

P. Emery, Z. Tallóczy, J. Braun, 2018, Saturday, 16 JUNE 2018.

OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY

D. M. van der Heijde, L. Gensler, P. Pertel, 2023, Annals of the Rheumatic Diseases.

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

D. Heijde, A. Deodhar, S. Visvanathan, 2008, Annals of the rheumatic diseases.

Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study

V. Strand, S. Blackburn, A. Deodhar, 2019, Clinical Rheumatology.

AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

J. Merola, E. Rampakakis, W. Boehncke, 2023, Annals of the Rheumatic Diseases.

LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study

M. Dougados, D. M. van der Heijde, A. Deodhar, 2018, WEDNESDAY, 13 JUNE 2018.

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

A. Racewicz, A. Deodhar, John D. Isaacs, 2010, Annals of the rheumatic diseases.